MAY 14 2026
AstraZeneca — Fasenra (benralizumab) $AZN
for Hypereosinophilic Syndrome
FDA approved AstraZeneca's Fasenra for adult and pediatric patients aged 12+ with hypereosinophilic syndrome without an identifiable non-hematologic cause.
About
Hypereosinophilic syndrome is a condition where the body produces too many eosinophils, a type of white blood cell, which can damage the heart, nerves, or bone marrow. Fasenra (benralizumab) is an antibody that binds to a specific receptor on eosinophils, marking them for rapid depletion by the immune system. By directly and quickly removing these excess cells, Fasenra may help control the tissue damage that defines this serious disease.
Pivotal trial
This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller medications.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Fasenra
- AstraZeneca secures label expansion for asthma blockbuster Fasenra in India - ETPharma.com
- Anna Leigh Waters V Ava Ignatowich At The Fasenra Virginia Beach Cup Presented By Joola Contante (8frQkvxike) - Mshale
- CDSCO Approves AstraZeneca's Fasenra for Hypereosinophilic Syndrome in India - Medical Dialogues
- Astrazeneca Pharma India Receives Permission To Import Benralizumab (Fasenra) For Additional Indication - TradingView
- AstraZeneca Pharma India gets CDSCO nod for additional Fasenra indication - Business Standard